ADMA - ADMA BIOLOGICS, INC.

10.78
-0.100   -0.928%

Share volume: 5,233,679
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$10.88
-0.10
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
66%
Profitability 81%
Dept financing 26%
Liquidity 75%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.09%
1 Month
-20.68%
3 Months
-38.05%
6 Months
-28.89%
1 Year
-49.60%
2 Year
73.87%
Key data
Stock price
$10.78
P/E Ratio 
0.00
DAY RANGE
$10.64 - $11.33
EPS 
$0.62
52 WEEK RANGE
$7.21 - $25.67
52 WEEK CHANGE
-$50.39
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,227,361
AVERAGE 30 VOLUME 
$10,411,914
Company detail
CEO: Adam S. Grossman
Region: US
Website: admabiologics.com
Employees: 530
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.

Recent news